Total Valuation
Samil Pharmaceutical Co., Ltd. has a market cap or net worth of ₩134.26B. The enterprise value is ―.
Market Cap₩134.26B
Enterprise Value―
Share Statistics
Samil Pharmaceutical Co., Ltd. has 21,691,810 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding21,691,810
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Samil Pharmaceutical Co., Ltd.’s return on equity (ROE) is -0.26 and return on invested capital (ROIC) is -6.80%.
Return on Equity (ROE)-0.26
Return on Assets (ROA)-0.09
Return on Invested Capital (ROIC)-6.80%
Return on Capital Employed (ROCE)-0.13
Revenue Per Employee359.60M
Profits Per Employee-59.25M
Employee Count585
Asset Turnover0.57
Inventory Turnover4.10
Valuation Ratios
The current PE Ratio of Samil Pharmaceutical Co., Ltd. is ―. Samil Pharmaceutical Co., Ltd.’s PEG ratio is -0.01.
PE Ratio―
PS Ratio0.98
PB Ratio1.54
Price to Fair Value1.54
Price to FCF-15.23
Price to Operating Cash Flow16.85
PEG Ratio-0.01
Income Statement
In the last 12 months, Samil Pharmaceutical Co., Ltd. had revenue of 210.37B and earned -34.59B in profits. Earnings per share was -1.63K.
Revenue210.37B
Gross Profit67.44B
Operating Income-23.94B
Pretax Income-37.16B
Net Income-34.59B
EBITDA-10.72B
Earnings Per Share (EPS)-1.63K
Cash Flow
In the last 12 months, operating cash flow was 7.87B and capital expenditures -10.20B, giving a free cash flow of -2.33B billion.
Operating Cash Flow7.87B
Free Cash Flow-2.33B
Free Cash Flow per Share-107.50
Dividends & Yields
Samil Pharmaceutical Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.05
52-Week Price Change-43.45%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)91.98K
Important Dates
Samil Pharmaceutical Co., Ltd. upcoming earnings date is Aug 7, 2026, TBA (Confirmed).
Last Earnings DateMay 18, 2026
Next Earnings DateAug 7, 2026
Ex-Dividend Date―
Financial Position
Samil Pharmaceutical Co., Ltd. as a current ratio of 0.44, with Debt / Equity ratio of 129.15%
Current Ratio0.44
Quick Ratio0.25
Debt to Market Cap0.79
Net Debt to EBITDA-14.70
Interest Coverage Ratio-2.73
Taxes
In the past 12 months, Samil Pharmaceutical Co., Ltd. has paid -2.49B in taxes.
Income Tax-2.49B
Effective Tax Rate0.07
Enterprise Valuation
Samil Pharmaceutical Co., Ltd. EV to EBITDA ratio is -33.90, with an EV/FCF ratio of -26.89.
EV to Sales1.73
EV to EBITDA-33.90
EV to Free Cash Flow-26.89
EV to Operating Cash Flow-59.99
Balance Sheet
Samil Pharmaceutical Co., Ltd. has ₩1.19B in cash and marketable securities with ₩166.03B in debt, giving a net cash position of -₩164.84B billion.
Cash & Marketable Securities₩1.19B
Total Debt₩166.03B
Net Cash-₩164.84B
Net Cash Per Share-₩7.60K
Tangible Book Value Per Share₩6.01K
Margins
Gross margin is 33.56%, with operating margin of -11.38%, and net profit margin of -16.44%.
Gross Margin33.56%
Operating Margin-11.38%
Pretax Margin-17.66%
Net Profit Margin-16.44%
EBITDA Margin-5.10%
EBIT Margin-11.38%
Analyst Forecast
The average price target for Samil Pharmaceutical Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-3.30%
EPS Growth Forecast-179.62%